Health

Detailed analysis of the neurodegenerative disorders market sector



07.11.2009 07:21:18 Bharatbook.com added a new report on "World Neurodegenerative Diseases Market 2009-2024" which provides current trends and future directions in neurodegenerative disorder therapies.

(live-PR.com) - World Neurodegenerative Diseases Market 2009-2024
The ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer's disease and Parkinson's disease - will lead to further expansion of the neurodegenerative therapies market. Increasing disease prevalence and a robust pipeline make that sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our

 

new report - World Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where the most-exciting developments will lie from the present onwards. In our pipeline analyses we include emerging therapeutics such as stem cells, gene therapy and monoclonal antibodies, among other prominent developments. ( http://www.bharatbook.com/Market-Research-Reports/World-Neurodegenerative-Diseases-Market-2009-2024.html )

This report examines markets for treating the following disorders in particular:
• Parkinson's disease • Alzheimer's disease • Multiple sclerosis • Amyotrophic lateral sclerosis • Neuropathies.

Also covered are the following neurodegenerative disorders:
• Huntington’s disease • Prion diseases.

What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market area? Where will the best commercial opportunities lie from 2009 onwards? What are the most-crucial drivers and restraints in this market? This report will provide you with the information that you need to understand current trends and future directions in neurodegenerative disorder therapies. In particular, we discuss prospects for the following products in detail:

• Sifrol • Stalevo • Requip • Aricept • Namenda • Exelon • Reminyl • Avonex • Copaxone • Rebif • Betaferon • Rilutek.

In this report you will receive the following benefits in particular:
• You will assess the current market for neurodegenerative disease therapeutics
• You will review the overall neurodegenerative disease therapeutics market, including a global sales forecast for 2009 to 2024
• You will receive sales forecasts for neurodegenerative disorder submarkets from 2009 to 2024, with detailed discussions
• You will receive sales forecasts for leading products from 2009 to 2024, with detailed discussions of market potential and competition
• You will receive sales forecasts for leading geographical markets from 2009 to 2024, with informed discussion
• You will examine commercial drivers and restraints in depth
• You will discover the most-exciting pipeline developments in the sector, with informed commentary
• You will discover expert opinions from our original survey of the sector, with prominent contributions from industry and academia.

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/Market-Research-Reports/World-Neurodegenerative-Diseases-Market-2009-2024.html

Or

Contact us at :
 
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook


Contact information:
Bharat Book Bureau

CBD Belapur,Mumbai

Contact Person:
Sandhya

Phone: + 91 22 27578668
eMail: eMail

Web: http://www.bharatbook.com

Author:
Sandhya Nair
e-mail
Web: http://globalknowledgeresearch.com
Phone: +91 22 27578668


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article
Terms Of Use Privacy About Live-PR.com Contact Us